Cargando…
Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers
Ovarian cancer (OC) is a lethal gynecologic malignancy, with modest responses to CPI. Engagement of additional immune arms, such as NK cells, may be of value. We focused on Siglec-7 as a surface antigen for engaging this population. Human antibodies against Siglec-7 were developed and characterized....
Autores principales: | Bordoloi, Devivasha, Kulkarni, Abhijeet J., Adeniji, Opeyemi S., Pampena, M. Betina, Bhojnagarwala, Pratik S., Zhao, Shushu, Ionescu, Candice, Perales-Puchalt, Alfredo, Parzych, Elizabeth M., Zhu, Xizhou, Ali, Ali R., Cassel, Joel, Zhang, Rugang, Betts, Michael R., Abdel-Mohsen, Mohamed, Weiner, David B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619929/ https://www.ncbi.nlm.nih.gov/pubmed/37910620 http://dx.doi.org/10.1126/sciadv.adh4379 |
Ejemplares similares
-
Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity
por: Choi, Hyeree, et al.
Publicado: (2021) -
A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy
por: Bordoloi, Devivasha, et al.
Publicado: (2022) -
Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape
por: Park, Daniel H., et al.
Publicado: (2023) -
DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas
por: Zhu, Xizhou, et al.
Publicado: (2021) -
Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2
por: Saini, Pratima, et al.
Publicado: (2023)